Background: The optimal approach to carotid revascularization in female patients with carotid artery stenosis is widely debated. Information available is largely derived from clinical trials that include only highly selected patients. The goal of this study was to compare the early clinical outcomes in women who undergo carotid artery stenting (CAS) vs carotid endarterectomy (CEA).
Few topics in surgery have proven as polarizing as the current debate surrounding the use of carotid artery stenting (CAS) for the management of carotid stenosis, and for few groups of patients is this debate more pronounced than for women. 1, 2 Studies that have sought to identify risk factors for stroke or death after CAS have produced conflicting results with regard to the impact of gender on poststenting outcomes. [3] [4] [5] [6] [7] [8] [9] Furthermore, although many analyses have failed to demonstrate any type of gender disparity in the comparative effectiveness of CAS vs carotid endarterectomy (CEA), still others have suggested that female patients who undergo CAS are at a significantly greater risk for postoperative stroke or death compared with female patients who undergo CEA. [10] [11] [12] [13] [14] [15] [16] Most comparisons of outcomes after CAS vs CEA in female patients either have used administrative data sources or have included only patients who were enrolled in randomized clinical trials. Administrative claims-based data have proven unreliable in the ability to adjust for the presence of symptoms attributable to carotid disease, to identify anatomic or physiologic "high-risk" patients, and to ascertain whether a perioperative stroke has occurred before or after carotid revascularization. [17] [18] [19] In addition, the applicability of conclusions that derive from analyses of clinical trial participants to a more general population of carotid stenosis patients has also been questioned. 3, [20] [21] [22] As a result, current knowledge about the comparative effectiveness of CAS and CEA for female patients outside of a clinical trial setting is limited at best. The recent introduction of the Procedure Targeted American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) offers an opportunity to improve our understanding of the impact of revascularization technique on the outcomes of women with carotid stenosis. The procedure-targeted iteration of the larger ACS NSQIP program uses prospective medical chart abstraction by trained clinical reviewers to collect clinical information that has previously been demonstrated to be highly reliable. 23 Moreover, the procedure-targeted data sets contain information about preoperative and postoperative variables that are of specific import to the analysis of outcomes after carotid revascularization, including the presence and severity of preoperative neurologic symptoms, the use of perioperative medications such as antiplatelet agents, and the 30-day occurrence of clinically relevant neurologic complications. 24 As of 2015, there were 89 academic or community hospitals participating in the CEA-targeted NSQIP program and 22 centers participating in the CAS-targeted program. 24 The objective of our study was therefore to use this "real-world" clinical repository of carotid revascularization patients to compare the early postoperative outcomes of CAS and CEA in women.
METHODS
The 2012 to 2015 CEA-and CAS-targeted ACS NSQIP Participant Use Data Files were used for this analysis. We included all female patients undergoing either CEA or CAS for an operative diagnosis of carotid artery stenosis (as indicated by an International Classification of Diseases, Ninth Revision, Clinical Modification code of 433.1, 433.10, or 433.11). The Institutional Review Board at University of Wisconsin approved the use of deidentified data, and informed consent was waived. Missing data were handled in one of two ways. For variables in which <0.5% of patients from the study population were missing information, patients with missing data were excluded from the analysis. For variables in which >0.5% of patients were missing information, a missing indicator was used. 25 We excluded those patients with an American Society of Anesthesiologists physical status classification of 5 (ie, moribund). The primary outcome variable for our analysis was the 30-day postoperative incidence of a major adverse clinical event (MACE), a composite outcome that included death, ipsilateral stroke, ipsilateral transient ischemic attack, and myocardial infarction (MI)/arrhythmia. 24 MI/arrhythmia was defined as one or more of the following: documentation of electrocardiography changes indicative of acute MI; new elevation in troponin more than three times the upper level of the reference range in the setting of suspected myocardial ischemia; diagnosis of MI by a physician; or documentation of a new cardiac arrhythmia that required some form of treatment. Secondary outcomes included the individual components of the primary composite outcome variable as well as the 30-day incidence of bleeding, reoperation, prolonged postoperative hospitalization (defined as >2 days), nonhome discharge, and hospital readmission. Postoperative bleeding is defined by the ACS NSQIP as "[the transfusion of] at least one unit of packed or whole red blood cells given from the surgical start time up to and including 72 hours postoperatively." 26 The primary predictor variable for our analysis was revascularization technique (CEA vs CAS). Other potential predictor variables are listed in Table I 26 Patients were considered to have been using antiplatelet agents, statins, or beta blockers if they were taking these medications at the time when a decision for surgery was made.
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Baseline patient-and procedure-related characteristics of female patients undergoing CEA vs CAS were compared for the entire study population using Pearson c 2 tests. In recognition of the possibility that there were likely to be nonrandom differences between female patients who underwent CEA and those who underwent CAS, we used propensity score matching techniques to create a cohort of patients from the entire study population who were matched on their propensity for undergoing CAS rather than CEA. For this analysis, a logistic regression model was created to estimate the likelihood of undergoing CAS (rather than CEA) using all of the variables listed in Table I as potential predictors of revascularization technique. The logit coefficients from this model were then used to create a propensity score for undergoing CAS for each patient from the entire study population that ranged from 0 to 1 and represented the likelihood of undergoing CAS rather than CEA. These propensity scores were then used to create an evenly matched cohort of female CEA and CAS patients by a caliper matching algorithm (caliper distance, 0.005), with patients being used only once in the matching. The desired result of this process was to pair as many CAS patients as possible with a corresponding CEA patient who was otherwise similar with respect to their comorbid and carotid disease profiles. Comparisons of preoperative characteristics and postoperative outcomes of this matched cohort of patients were then performed using conditional logistic regression models, with statistical significance being defined as P < .05. In addition to these analyses, we also conducted a secondary univariate comparison of those patients in our overall study population who were noted to have one or more anatomic high-risk factors. Stata version 12 (StataCorp LP, College Station, Tex) was used for all statistical analyses.
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RESULTS
A total of 5796 patients met the inclusion criteria for our study. Of these patients, 46 patients were excluded for missing information and one patient was excluded for an American Society of Anesthesiologists classification of moribund, yielding a study population of 5751 patients. Of these patients, 5620 (97.7%) underwent CEA and 131 (2.3%) underwent CAS.
The patient-and procedure-related characteristics of our study population, stratified by revascularization technique, are shown in Table I 6%] of CEA patients; P < .001). There was not a significant difference between treatment groups with respect to preoperative symptom status, with >50% of both groups having asymptomatic carotid disease. CAS patients were significantly more likely to have one or more anatomic or physiologic high-risk factors than CEA patients and were also more likely than CEA patients to be taking an antiplatelet medication before their revascularization procedure. Finally, female CAS patients were more likely than CEA patients to have a provider other than a vascular surgeon perform their procedure.
The postoperative outcomes of patients from the overall study population are shown in Table II . The 30-day incidence of MACE was 5.2% (290 patients) after CEA compared with 12.2% (16 patients) after CAS (P < .001). Analysis of secondary outcomes demonstrated CAS patients to have a higher incidence of MI/arrhythmia and bleeding compared with CEA patients. There were no other significant differences in secondary outcomes of the entire study population when stratified by revascularization technique. Among the asymptomatic patients in our overall study population, the 30-day incidence of MACE was 8.2% (6 of 73 patients) after CAS and 4.3% (141 of 3287 patients) after CEA (P ¼ .1); among the symptomatic patients, the incidence was 15.4% (8 of 52 patients) after CAS vs 6.7% (148 of 2221 patients) after CEA (P ¼ .01).
Our algorithm for matching patients based on their propensity for undergoing CAS resulted in the creation of a cohort of 125 CAS and 125 CEA patients. Comparison of the patient-and procedure-related characteristics of these patients is shown in Table III , which demonstrates that the two groups in this cohort were well matched for all known variables. A comparison of the primary outcomes of this matched cohort (Table IV) demonstrated a 30-day incidence of MACE of 11.2% (14 patients) in the CAS group compared with 4.0% (5 patients) in the CEA group (odds ratio, 2.8 [95% confidence interval, 1.01-7.77]; P ¼ .04). The secondary outcomes of the propensity-matched cohort are also depicted in Table IV and did not exhibit any significant differences between the two groups. We also conducted a secondary analysis of those female patients from our overall study population stratified by the presence or absence of one or more anatomic high-risk factors. Among those women without any such factors, the 30-day incidence of postoperative MACE was 5.1% (253 of 4979 patients) after CEA vs 10.1% (7 of 69 patients) after CAS (P ¼ .06). Among those women with one or more anatomic high-risk factors, the 30-day incidence of postoperative MACE was 6.4% (36 of 567 patients) after CEA vs 14.8% (9 of 61 patients) after CAS (P ¼ .02).
DISCUSSION
Our analysis of data from the Procedure Targeted ACS NSQIP registry demonstrates that women with carotid stenosis who undergo CAS have a substantially greater risk of major adverse outcomes compared with women who undergo CEA. The 30-day incidence of postoperative MACE after CAS in our study was 12.2%, compared with an incidence of 5.2% after CEA. In comparing a cohort of 250 female patients who were well matched for all known patient-, disease-, and procedure-related variables, this marked difference in the early outcomes of CAS vs CEA maintained statistical significance. Although the modest size of the CAS group in our study prevented a robust analysis of the individual components of our primary composite outcome, the rates of death, stroke, transient ischemic attack, and MI/arrhythmia all appeared to be higher after CAS than after CEA. Taken together, the findings of our study suggest that within the context of short-term periprocedural risk, CAS may be inferior to CEA in female patients who require carotid revascularization.
Several large studies published previously have also suggested that CEA may be the preferred intervention for women with carotid stenosis. In their analysis of 20,620 female patients from the Florida and New York state hospital discharge databases, Vouyouka et al found that women who underwent CAS had a 2.39-fold higher rate of in-hospital postoperative stroke or death after risk adjustment compared with women who underwent CEA. 15 Because of the large sample size in that study, the authors were able to stratify their analyses by preoperative symptom status and found that the outcome disparity between the two procedures was present for both symptomatic and asymptomatic women. Rockman et al used data from the 2004 to 2005 Nationwide Inpatient Sample to compare the in-hospital postoperative outcomes of 21,621 female CEA patients with those of 1199 female CAS patients. Although no risk adjustment was performed in the study, the authors found that the incidence of both stroke (2.7% after CAS vs 1.0% after CEA; P < .001) and death (1.1% after CAS vs 0.5% after CEA; P ¼ .005) was higher after stenting. 13 Finally, Howard et al performed a prespecified secondary analysis of data from the Carotid Revascularization Endarterectomy vs Stenting Trial (CREST) to compare 30-day postoperative outcomes of CAS vs CEA in 872 female patients. 14 The 30-day combined incidence of stroke, death, or MI for women undergoing CAS in this analysis was 6.8% compared with an incidence of 3.8% in women undergoing CEA (hazard ratio, 1.84; 95% confidence interval, 1.01-3.37; P ¼ .047). A potential limitation of these studies derives from the populations of patients that were used. Administrative data derived from sources such as the Nationwide Inpatient Sample and hospital discharge databases have been proven unreliable for determination of nonfatal postoperative outcomes such as stroke and MI. 17, 18 Such data sources have also been found lacking in their ability to decipher the presence or absence of critical factors such as preoperative cerebrovascular symptoms, even when "present on admission" indicators are used. 17, 18 The extent of these limitations has led some investigators to conclude that administrative data should not be used for carotid revascularization outcomes analyses. 17 Data that emanate from clinical trials, on the other hand, have been criticized not for a lack of reliability but instead for a lack of generalizability to real-world practice. For example, Mudra et al found that the comorbidity profiles of a sizable proportion of their center's large cohort of CAS patients would have rendered them ineligible for participation in the CREST trial. 21 The strict criteria that are used to determine eligibility of patients for CREST and other trials and the minimum experience thresholds that are typically required of proceduralists in these trials likely explain why poststenting outcomes in clinical trials are generally superior to those realized in the nontrial setting. 20, 22 Our use of the Procedure Targeted ACS NSQIP database therefore provides a unique and, some would suggest, necessary real-world perspective to the debate about choice of revascularization technique in women with carotid stenosis.
3,21 Although we were unable to compare longer term postoperative outcomes of the two procedures or to explore how preoperative symptom status might affect the comparative outcomes, the findings of our analysis should nevertheless raise some concern about the use of CAS in female patients. Potential reasons for the suggested association between the patient's gender and poor poststenting outcomes have been offered, including, among others, the smaller diameter of female vessels and the tendency for atherosclerotic plaques in female patients to be centered within the common carotid artery rather than the internal carotid artery. Ultimately, however, the underlying mechanisms for the differential outcomes of CAS and CEA that we demonstrate are not yet fully understood.
In our secondary analysis of female patients from our overall study cohort who demonstrated one or more anatomic high-risk factors, we found that the 30-day incidence of MACE was significantly higher after CAS than after CEA (14.8% vs 6.4%). Although the presence of such risk factors is often used as a justification for performing CAS rather than CEA, there is little evidence to actually support this practice. Several studies that have compared the two procedures in patients with contralateral carotid occlusion, prior ipsilateral CEA, or prior neck irradiation have failed to demonstrate any appreciable difference in the outcomes of the two procedures. [27] [28] [29] [30] Although our sample of female patients was relatively small and our secondary analysis of anatomic high-risk women was not subject to risk adjustment, our findings suggest that CEA may be a reasonable if not preferable alternative to CAS even in those patients with anatomic high-risk factors.
Our study has several important limitations. As previously acknowledged, the relatively small number of CAS patients in our study population prohibits us from stratifying our outcomes analyses by preoperative symptom status or from performing robust statistical analyses of individual outcomes, such as postoperative stroke. In addition, although the procedure-targeted data sets used for our analysis contain information on factors germane to the analysis of postrevascularization outcomes, information about procedure volume, atherosclerotic plaque characteristics, and other potentially relevant variables is not known. 31 Furthermore, the ACS NSQIP presents information about Centers for Medicare and Medicaid Services-defined anatomic and physiologic high-risk factors as a composite, which prevents our ability to adjust for the potential effects of the individual factors in comparing outcomes of the two revascularization techniques. Similarly, the ACS NSQIP captures the occurrence of MI or new-onset arrhythmia only as a composite outcome. The results of our study are therefore not directly comparable to previously published clinical comparisons of carotid revascularization strategy because such comparisons typically report the incidence of only postoperative MI (not arrhythmia). Finally, our study does not address the larger question of whether medical therapy, rather than any type of revascularization procedure, might be the preferred management approach in women with carotid artery disease.
CONCLUSIONS
Despite these limitations, our analysis of CAS and CEA procedures in female patients who are included in the Procedure Targeted ACS NSQIP data sets demonstrates a higher incidence of composite adverse postoperative outcomes in CAS patients. The findings of our study suggest that further investigation of the role of the patient's gender in outcomes of carotid revascularization is merited and that women who are deemed suitable for intervention may be better served by CEA. 
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